145 related articles for article (PubMed ID: 20809534)
1. Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes.
O'Sullivan EP; Ashley DT; Davenport C; Devlin N; Crowley R; Agha A; Thompson CJ; O'Gorman D; Smith D
Diabetes Metab Res Rev; 2010 Sep; 26(6):496-502. PubMed ID: 20809534
[TBL] [Abstract][Full Text] [Related]
2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
3. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
5. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes.
Shin JY; Shin YG; Chung CH
Diabetes Care; 2006 Jul; 29(7):1664-6. PubMed ID: 16801598
[No Abstract] [Full Text] [Related]
7. The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients.
Davenport C; Kenny H; Ashley DT; O'Sullivan EP; Smith D; O'Gorman DJ
Eur J Clin Invest; 2012 Nov; 42(11):1173-9. PubMed ID: 22803952
[TBL] [Abstract][Full Text] [Related]
8. Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?
Castellino G; Corallini F; Trotta F; Secchiero P
Ann Rheum Dis; 2008 Aug; 67(8):1196-7. PubMed ID: 18621972
[No Abstract] [Full Text] [Related]
9. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.
Anand DV; Lahiri A; Lim E; Hopkins D; Corder R
J Am Coll Cardiol; 2006 May; 47(9):1850-7. PubMed ID: 16682312
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
14. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity.
Kim SM; Lee J; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
Clin Endocrinol (Oxf); 2005 Nov; 63(5):594-8. PubMed ID: 16268814
[TBL] [Abstract][Full Text] [Related]
16. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
18. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein.
Sennels HP; Jacobsen S; Jensen T; Hansen MS; Ostergaard M; Nielsen HJ; Sørensen S
Scand J Clin Lab Invest; 2007; 67(8):821-35. PubMed ID: 17852826
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.
Venuraju SM; Yerramasu A; Corder R; Lahiri A
J Am Coll Cardiol; 2010 May; 55(19):2049-61. PubMed ID: 20447527
[TBL] [Abstract][Full Text] [Related]
20. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.
Secchiero P; Corallini F; Pandolfi A; Consoli A; Candido R; Fabris B; Celeghini C; Capitani S; Zauli G
Am J Pathol; 2006 Dec; 169(6):2236-44. PubMed ID: 17148684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
